

19 DEC 2006

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

KRIEGSMAN & KRIEGSMAN 30 TURNPIKE ROAD, SUITE 9 SOUTHBOROUGH MA 01772

In re Application of ALKEN Application No.: 10/539,793

PCT No.: PCT/DE03/04204 Int. Filing: 18 December 2003

Priority Date: 19 December 2002

Attorney Docket No.: 82444 For: USE OF L-DOPA, DERIVATIVES,

THEREOF AND MEDICAMENTS COMPRISING SAID COMPOUNDS FOR THE PROPHYLAXIS

OF PSYCHOTIC DISEASES

DECISION ON

PETITION TO REVIVE

UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 18 November 2006 in the abovecaptioned application is hereby **GRANTED** as follows:

Applicant's statement that the "entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" meets the requirements of 37 CFR 1.137(b)(3).

A review of the application file reveals that an executed declaration and an English translation of the international application have now been submitted. The required petition fee of \$750 was also paid. Thus, the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being forwarded to the United States Designated/Elected Office for further processing. The 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) date is 18 November 2006.

Cynthia M. Kratz Attorney Advisor

PCT Legal Office

Office of PCT Legal Administration

Telephone: (571) 272-3286 Facsimile: (571) 273-0459